)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
Sight Sciences (SGHT) investor relations material
Sight Sciences Morgan Stanley 23rd Annual Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Morgan Stanley 23rd Annual Global Healthcare Conference summary10 Sep, 2025
Market overview and trends
Glaucoma remains a leading cause of irreversible blindness, with a growing need for minimally invasive treatments and ongoing innovation in the MIGS market despite current reimbursement headwinds.
The MIGS market is expected to return to growth in 2026 as current headwinds from LCDs are anticipated to subside by Q4, with patient visits continuing to increase.
The prevalence of glaucoma is expected to rise globally due to factors like aging, diabetes, and hypertension, driving demand for new technologies.
Future glaucoma treatment is expected to become increasingly interventional, with sustained-release interventions, broader MIGS options, and higher utilization of SLT laser.
Early intervention and education for both providers and patients are emphasized as critical for improving outcomes in glaucoma and dry eye.
Company performance and product innovation
Despite mid-single digit declines in surgical glaucoma revenue, performance outpaced the 15% headwind from multiple MIGS restrictions, with record ordering accounts and increased utilization.
OMNI Edge, the latest iteration of the OMNI platform, nearly doubles the dilation effect in canaloplasty, receiving strong surgeon adoption and positive feedback.
Continuous innovation is planned for the OMNI platform, with further product iterations in development to maintain technological leadership.
Success in the MIGS market is attributed to a combination of technology, safety, efficacy, usability, and strong surgeon relationships.
Dry eye market and TearCare
TearCare targets the root cause of most dry eye cases—meibomian gland dysfunction—using a wearable, in-office device that heats and clears gland blockages.
Two RCTs, including the Sahara study, demonstrated TearCare’s superiority to standard care, with durable improvements in signs and symptoms over 24 months.
The company is actively engaging payers, leveraging robust clinical and economic evidence to secure reimbursement, aiming for policy wins by 2025.
Over 1,500 SmartHubs are already installed, positioning the company to rapidly scale patient access once reimbursement is secured.
TearCare offers a compelling value proposition for patients, providers, and payers, with potential for high adoption once coverage is achieved.
Payer concerns on multiple MIGS efficacy
OMNI Edge: Key innovation and surgeon feedback
TearCare: Payer strategy for 2025 policy wins
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Sight Sciences earnings date
Q3 20256 Nov, 2025
Next Sight Sciences earnings date
Q3 20256 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
)
Edge19 Sep 2025
American Express: An Empire of Plastic
How history, brand, and structure have steadily built American Express' moat, and why Warren Buffett still calls it a one-of-a-kind business.
Frequently asked questions
Sight Sciences, Inc. is a medical technology company focused on developing and commercializing treatments for eye diseases. The company's main business is centered around creating devices that address conditions affecting the eye, particularly in the areas of glaucoma and dry eye disease. Sight Sciences' products are designed to improve patient outcomes by offering minimally invasive solutions that target the underlying causes of these conditions. It serves the ophthalmology and optometry sectors, providing tools for healthcare professionals to enhance the treatment of common but serious eye health issues. The company is headquartered in Menlo Park, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage